Pfizer ( PFE 1.46%) made a fortune thanks to its work in the COVID-19 market. In 2022, it became the first company in the ...

Pfizer jumps into cancer-treatment race with a $6 billion licensing deal with a China-based company, six months after Merck’s ...

Pfizer remains a strong Buy with robust cost controls, EPS growth, and a promising pipeline, despite challenges. See more on ...

Although the immediate market response was negative, most pharmaceutical stocks recovered after Wall Street analysts emphasized the considerable legal obstacles the ...

U.S. drugmaker Pfizer said it would license an experimental cancer treatment from China's 3SBio Inc , paying $1.25 billion ...

Bispecific anti-PD1/VEGF remains one of the hottest topics in the oncology field. Click here for a detailed analysis.

Here is why Pfizer can't seem to get off the mat and whether it's worth buying the dip on today. I won't rehash Pfizer's pandemic journey too much. The company developed and sold a vaccine (Comirnaty) ...

Pfizer announced last month that it was discontinuing development of its experimental weight-loss pill, danuglipron, after a trial participant experienced potential drug-induced liver injury.

He added that Pfizer is being "very frugal" with investments so it can be "prepared ... billionaire investor Mark Cuban said in March that drugs from his company, Cost Plus Drugs, will likely ...

The drug giant continues to face an "uncertain and volatile external environment," he said. Pfizer's stock rose ... of products and services to both investment professionals and individual investors.